Medicare (02159) announced interim results with profit attributable to owners of 17.903 million yuan, which turned a year-on-year loss into profit

According to the Zhitong Finance App, Medi Weikang (02159) announced the 2026 interim results, with revenue of about 231 million yuan, an increase of about 81.7% year on year; gross profit of about 69.7 million yuan, up about 219.7% year on year; profit due to company owners of 17.903 million yuan, which turned a loss into a profit; profit per share of 7.85 points.

During the reporting period, the Group's main businesses maintained steady operation and continued to empower the business scenario through technological innovation. Relying on deep accumulation and massive professional resources in the healthcare field, the Group has steadily increased the service depth and application coverage of digital intelligence products. While consolidating traditional advantageous businesses, the Group is actively expanding its innovative business layout and comprehensively optimizing operational efficiency. The Group's overall management remains efficient and orderly, and the business structure continues to be upgraded to high value-added fields, laying a solid foundation for sustainable growth and long-term value reshaping throughout the year.

At the level of core strategy and technological innovation, the Group continues to deepen the development and scenario-based implementation of the “AI Vertical Model+Blockchain” underlying architecture, and is committed to solving the industry pain points of the General Model in the field of depth of expertise and data compliance. During the reporting period, the Group's core technology carrier “Giraffe Digital Intelligence Integrated Platform” completed phased upgrades and iterative operations, further opening up the deep integration of AI intelligence, medical specialist knowledge base and clinical business flow. In terms of building specialized disease models, on the basis of consolidating superior specialties such as cerebrovascular disease, the Group is actively expanding horizontally into high-incidence diseases such as cardiovascular and respiratory diseases, and continuously enriches the structured specialist corpus.